DrugDashboards

Vivimusta

Bendamustine Hydrochloride · BENDAMUSTINE HYDROCHLORIDE 25 mg/mL · Injection · Intravenous · Slayback Pharma LLC

NDC 71225-0120-01 · 1 VIAL, MULTI-DOSE in 1 CARTON / 4 mL in 1 VIAL, MULTI-DOSE · NDA · View full market →

The short version

5 companies supply this market — a reasonable cushion if one runs into trouble.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

One drug, every price

The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.

ⓘ How this was built
Data sources
  • CMS NADAC (pharmacy acquisition, weekly)
  • CMS Part B ASP quarterly payment limits
  • CMS Maximum Fair Prices (IRA negotiated, NDC-level)
  • Medicare Part D Spending by Drug (data.cms.gov, name-matched)
  • VA FSS / Big4 federal contract prices (va.gov, twice monthly)
  • ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
  • California SB-17 WAC filings (list price, per package)
Method

Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

  • Medicare Part B pays (ASP+6%)$29.91per billing unit (1 MG)HCPCS J9056 · Jul 1, 2026
  • Federal ceiling (Big4)$1,303.98per package of 4MLSlayback Pharma LLC · Jan 1, 2026

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Estimated fill cost

WAC per package, as filed
$3,273.73
Reported to Texas DSHS · 2026 annual filing · Slayback Pharmaceuticals, Inc.

Manufacturer list price as filed — not what pharmacies actually pay after discounts.

Medicare Part B (ASP)

Payment limit per 1 MG
$29.913
HCPCS J9056 · Jul 1, 2026 quarter · typically ASP + 6%

Medicaid spend (2025)

$361,387
125 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

Where it's made

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
NDA212209
TE code
Approval date
Dec 7, 2022
Patents / exclusivity
4 patents, 0 exclusivities
TypeNumber / codeExpires
patent12419867Jul 29, 2042
patent12208086Jul 29, 2042
patent11844784Jul 29, 2042
patent11707450Jul 29, 2042

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Bendamustine Hydrochloride (Injection)

LabelerStrengthFirst seenLast seen
Avyxa Pharma, LLCBENDAMUSTINE HYDROCHLORIDE 100 mg/4mLJul 15, 2026Sep 2, 2026
Azurity Pharmaceuticals, Inc.BENDAMUSTINE HYDROCHLORIDE 25 mg/mLJul 15, 2026Sep 2, 2026
Baxter Healthcare CorporationBENDAMUSTINE HYDROCHLORIDE 100 mg/1Jul 15, 2026Sep 2, 2026
Eagle Pharmaceuticals, IncBENDAMUSTINE HYDROCHLORIDE 100 mg/4mLJul 15, 2026Sep 2, 2026
Slayback Pharma LLCBENDAMUSTINE HYDROCHLORIDE 25 mg/mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Vivimusta — NDC 71225-0120-01," retrieved September 3, 2026, https://drugdashboards.com/drug/71225012001.

Free to cite with attribution — see how the data is put together.